REGENXBIO Inc.

REGENXBIO Inc. is a clinical-stage biotechnology company that focuses on the development and commercialization of gene therapies. The company utilizes its proprietary NAV Technology Platform to deliver genetic medicines for severe conditions. Its pipeline includes surabgene lomparvovec, RGX-121, and RGX-111, which are evaluated across clinical studies such as AAVIATE, ALTITUDE, and ATMOSPHERE. REGENXBIO provides development services, licensing rights, and technology access to partners. Its customers and collaborators primarily consist of global pharmaceutical and biotechnology companies, such as AbbVie and Nippon Shinyaku, as well as research institutions.

The company operates within the United States and maintains business relationships across international regions, including Ireland, Japan, Germany, and the United Arab Emirates. Its facilities include sites along Medical Center Drive in Maryland and leased space in New York. REGENXBIO is headquartered in Rockville, Maryland.

Summary of the business section of Regenxbio's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of February 27, 2026, we employed 371 full-time employees, of which 296 were engaged in research and development activities, including preclinical, clinical and manufacturing related functions, and 75 were engaged in general administrative activities, including commercial, corporate development, finance, legal, human resources, information technology, fac”